We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Medica 2024 Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Rapid Solutions for Point-of-Care Diagnostics Provided Worldwide

By LabMedica International staff writers
Posted on 15 Jun 2009
A range of rapid diagnostic tests used for the detection of infectious diseases offers fast and cost-effective clinical solutions for point-of-care diagnostic testing.

The QuickVue range includes qualitative detection of influenza type A and type B antigens, a dipstick immunoassay for acute respiratory syncytial virus (RSV) infections, and a one-step human chorionic gonadotropin (hCG) test, as well as quick and simple tests for Helicobacter pylori, Chlamydia, and Streptococcus group A infections.

BioMerieux (Marcy l'Etoile, France) is now supplying the QuickVue range of rapid diagnostic tests worldwide, as part of a global alliance with Quidel Corp. (San Diego, CA, USA) for the development and distribution of rapid clinical diagnostic solutions. Many new tests are in the development pipeline.

The long-term global alliance between Quidel and bioMérieux was originally formed in 2008. The two companies planned to codevelop new rapid tests using Quidel's rapid test development capability and bioMérieux's expertise in immunochemistry and wide-ranging library of biologics, including antibodies and antigens.

BioMerieux provides diagnostic solutions (reagents, instruments, software) that determine the source of disease and contamination. Its products are used for diagnosing infectious diseases, for providing results for cancer screening and monitoring, and cardiovascular emergencies.

Quidel develops rapid diagnostic tests that allow for the movement of patient testing out of the central laboratory setting and into the physician office, urgent care, and other outpatient settings where rapid testing and treatment has an impact on clinical outcomes and provides an economic benefit.

Related Links:

bioMerieux
Quidel



New
Gold Member
Syphilis Screening Test
VDRL Antigen MR
Antipsychotic TDM AssaysSaladax Antipsychotic Assays
New
Human Insulin CLIA
Human Insulin CLIA Kit
New
Free Human Prostate-Specific Antigen CLIA
LIAISON fPSA

Latest Immunology News

Simple Blood Test Could Detect Drug Resistance in Ovarian Cancer Patients

Advanced Imaging Method Maps Immune Cell Connections to Predict Cancer Patients Survival

Computational Tool Predicts Immunotherapy Outcomes for Metastatic Breast Cancer Patients